Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;21(9):580-597.
doi: 10.1016/j.clml.2021.05.016. Epub 2021 May 29.

Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades

Hagop M Kantarjian  1 , Nicholas J Short  2 , Amir T Fathi  3 , Guido Marcucci  4 , Farhad Ravandi  2 , Martin Tallman  5 , Eunice S Wang  6 , Andrew H Wei  7
Affiliations
Review

Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades

Hagop M Kantarjian et al. Clin Lymphoma Myeloma Leuk. 2021 Sep.

Abstract

With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML research and therapy, discuss insights regarding prognostic assessment and prediction of treatment outcome, detail practical supportive care measures, and summarize the current treatment landscape and areas of evolving research.

Keywords: AML; Biology; Prognosis; Targeted therapy; Therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure H.K. reports research grants and honoraria from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer, and Sanofi; and honoraria from Actinium (advisory board), Adaptive Biotechnologies, Aptitude Health, Bio Ascend, Delta Fly, Janssen Global, Oxford Biomedical, and Takeda Oncology. A.H.W. has served on advisory boards for Novartis, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Celgene-BMS, MacroGenics, Agios, and Gilead; receives research funding to the institution from Novartis, AbbVie, Servier, Celgene-BMS, Astra Zeneca, and Amgen; serves on speakers bureaus for AbbVie, Novartis, and Celgene; and receives royalty payments from the Walter and Eliza Hall Institute of Medical Research related to venetoclax. M.S.T. has served on advisory boards for AbbVie, Daiichi-Sankyo, Orsenix, KAHR, Delta Fly Pharma, Jazz Pharma, Roche, BioSight, Novartis, Innate Pharmaceuticals, Kura, and Syros Pharmaceuticals; received research funding from AbbVie, Orsenix, BioSight, GlycoMimetics, Rafael Pharmaceuticals, and Amgen; and received royalty from UpToDate. N.J.S. has received consulting fees from Takeda Oncology and AstraZeneca, research funding from Takeda Oncology and Astellas Pharma Inc, and honoraria from Amgen. A.T.F. has provided consulting/advisory services for Agios, BMS/Celgene, Astellas, Seattle Genetics, AbbVie, Pfizer, Genentech, Kite, Amgen, Takeda, Kura, Blueprint, Trillium, Foghorn, Amphivena, NewLink Genetics, Trovagene, Novartis, and MorphoSys. He is receiving research support from Agios, Celgene/BMS, and AbbVie. G.M. has received honoraria from Agios, AbbVie, and Novartis; research support from Merck ESW; has served on advisory boards for AbbVie, Astellas, BMS/Celgene, Genentech, GlaxoSmithKline, Jazz, Kite Pharmaceuticals, Kura Oncology, Novartis, Pfizer, Stemline, and Takeda; provided consulting for Mana Therapeutics; served as a speaker for Stemline, Kura, Pfizer, and DAVA Oncology; and served on data safety monitoring committees for AbbVie and Rafael Pharmaceuticals.

Figures

Figure 1.
Figure 1.
Survival of patients <60 years of age (A) and ≥60 years of age (B) with de novo AML treated at MD Anderson over five decades
Figure 1.
Figure 1.
Survival of patients <60 years of age (A) and ≥60 years of age (B) with de novo AML treated at MD Anderson over five decades
Figure 2.
Figure 2.
Survival in patients <60 years of age (A) and ≥60 years of age (B) with newly diagnosed APL treated at MD Anderson over five decades
Figure 2.
Figure 2.
Survival in patients <60 years of age (A) and ≥60 years of age (B) with newly diagnosed APL treated at MD Anderson over five decades
Figure 3.
Figure 3.
Survival in patients <60 years of age (A) and ≥60 years of age (B) with newly diagnosed CBF-AML treated at MD Anderson over five decades
Figure 3.
Figure 3.
Survival in patients <60 years of age (A) and ≥60 years of age (B) with newly diagnosed CBF-AML treated at MD Anderson over five decades
See this image and copyright information in PMC

References

    1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. - PMC - PubMed
    1. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol. 2015;1(6):820–8. - PubMed
    1. Kantarjian H, Kadia T, DiNardo C, et al. Acute Myeloid Leukemia—Current Progress and Future Directions. Blood Cancer Journal 2021: Feb 22;11(2):41. - PMC - PubMed
    1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896–903. - PubMed
    1. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–59. - PMC - PubMed

Publication types